R&D | January 21, 2026
Moderna & Merck study: mRNA therapy plus KEYTRUDA cut melanoma recurrence risk by half
The study evaluated patients with stage III/IV melanoma after complete tumor resection
The study evaluated patients with stage III/IV melanoma after complete tumor resection
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
Berendsen brings over 15 years of financial leadership experience spanning professional services and international trade
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
India in the Changing Landscape of Life-Sciences Research & Development
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
Subscribe To Our Newsletter & Stay Updated
